Overview
Crystagen (EDP) is a synthetic three-amino-acid peptide bioregulator designed specifically to support immune system organs and T-cell function.
What problem it targets: It targets chronic immune deficiency, high susceptibility to recurring seasonal illnesses, post-antibiotic immune depletion, and age-related immune decline.
What It Does
• Normalizes T-cell differentiation: Interacts with immune system cells to stimulate the proper maturation of T-lymphocytes, enhancing cell-mediated immune defense.
• Rebalances immune homeostasis: Restores equilibrium between helper and suppressor immune cells, boosting pathogen defense while preventing excessive chronic inflammation.
• Enhances cellular vitality during illness: Increases the functional activity and resilience of immune cells when challenged by infections, environmental stress, or surgery.
• Realistic expectations: Administered in short 10- to 20-day courses a few times per year. Systematically strengthens immune baseline defense rather than acting as a fast-acting decongestant.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Ageing-spleen research | Schedule not specified in the accessible abstract | Not reported in the accessible abstract | B-cell activation was reported, without ageing-spleen cell renewal. No validated human regimen identified. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
